Literature DB >> 10421710

Enhancement of N-methyl-D-aspartate (NMDA) immunoreactivity in residual dendritic spines in the caudate-putamen nucleus after chronic haloperidol administration.

J J Rodríguez1, V M Pickel.   

Abstract

Glutamate receptors of the N-methyl-D-aspartate (NMDA) subtype in the caudate-putamen nucleus (CPN) have been implicated in the adverse motor effects produced by chronic administration of the typical antipsychotic drug haloperidol. To determine the functionally relevant sites, we examined the electron microscopic immunocytochemical localization of the R1 receptor subunit (NMDAR1) in the dorsolateral CPN of rats receiving 4 months of biweekly depot intramuscular injections of either haloperidol or vehicle. In all animals, NMDAR1 immunoreactivity was seen mainly in dendritic spines, but was also present in a few somata and dendrites of spiny neurons, axon terminals, and glia. In comparison with controls, the dissector stereological analysis showed a significant reduction in the numerical density of total NMDAR1-labeled and unlabeled dendritic spines in the dorsolateral CPN after haloperidol administration. When labeled spines were identified separately based exclusively on the presence of immunoreactivity within a single plane of section, there was, however, a significant increase in the numerical density of NMDAR1-containing spines in haloperidol vs. control animals. This increase was not seen using a classic dissector, suggesting that the enhancement was mainly attributed to more frequent detection of spines having higher levels of NMDA immunoreactivity. Our results are the first to identify dendritic spines in the dorsolateral CPN as preferential sites for the regulated expression of NMDA receptors following chronic administration of haloperidol. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421710     DOI: 10.1002/(SICI)1098-2396(19990915)33:4<289::AID-SYN6>3.0.CO;2-I

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  7 in total

1.  Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.

Authors:  Bonnie G Garcia; M Diana Neely; Ariel Y Deutch
Journal:  Cereb Cortex       Date:  2010-01-29       Impact factor: 5.357

Review 2.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

3.  Ultrastructural localization of nitrotyrosine within the caudate-putamen nucleus and the globus pallidus of normal rat brain.

Authors:  E A Bolan; K N Gracy; J Chan; R R Trifiletti; V M Pickel
Journal:  J Neurosci       Date:  2000-07-01       Impact factor: 6.167

4.  Multimodal neuroimaging studies and neurodevelopment and neurodegeneration hypotheses of schizophrenia.

Authors:  Vicente Molina; Santiago Reig; Manuel Desco; Juan D. Gispert; Javier Sanz; Fernando Sarramea; Javier Pascau; Carlos Benito; Raul Martínez-Lázaro; Rogelio Luque; María Aragües; Jose M. Misiego; Ignacio López Corral; Thomás Palomo
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

5.  Dystrophic dendrites in prefrontal cortical pyramidal cells of dopamine D1 and D2 but not D4 receptor knockout mice.

Authors:  Hui-Dong Wang; Gregg D Stanwood; David K Grandy; Ariel Y Deutch
Journal:  Brain Res       Date:  2009-09-10       Impact factor: 3.252

Review 6.  Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism.

Authors:  Ariel Y Deutch; Roger J Colbran; Danny J Winder
Journal:  Parkinsonism Relat Disord       Date:  2007       Impact factor: 4.891

7.  Neurotoxicity of NMDA antagonists: a glutamatergic theory of schizophrenia based on selective impairment of local inhibitory feedback circuits.

Authors:  H Grunze; A Bender; S Wendhof; M Schäfer; D Rujescu
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.